Article

Neuropsychological sequelae of medulloblastoma in adults.

Department of Pediatrics, School of Medicine, University of California, San Francisco USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.18). 05/1997; 38(1):21-6. DOI: 10.1016/S0360-3016(96)00592-5
Source: PubMed

ABSTRACT To investigate the neuropsychological consequences of medulloblastoma in adults.
Patients 18 years of age or older who had medulloblastoma and at least 3 years of disease-free survival were eligible. A battery of tests was conducted to assess global intellectual functioning, verbal ability, visuospatial ability, memory, reasoning, and academic proficiency. For the verbal memory performance, each patient was matched with two normal controls selected on the basis of age, sex, and level of education.
Review of the Neuro-Oncology database revealed 24 patients eligible for the study. Of these, 10 patients (6 good-risk and 4 poor-risk) agreed to participate; 7 patients were lost to follow-up; 5 lived too far away to come to the testing site, and 2 refused testing. There were four men and six women; their mean age was 36.5 years at testing and 29.9 years at surgical diagnosis. Mean dose of whole brain radiation was 34.5 Gy. Mean interval between diagnosis and testing was 79.1 months. Test results demonstrated below average intelligence quotients (mean intelligence quotient 90.2; range 67-103) and specific deficits in memory, reasoning, visuospatial ability, and arithmetic.
Adults with medulloblastoma in a prolonged disease-free status may suffer significant cognitive deficits. We recommend further controlled, prospective studies to evaluate cognitive outcomes in this patient population in the hope that interventional strategies could be developed, or treatment modified to minimize such toxicities.

1 Follower
 · 
135 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMO Meduloblastomas representam 1% dos tumo-res intracranianos e 6% dos tumores de fossa posterior nos adultos. A incidência populacional neste grupo é de, aproximadamente, 0,5 milhão/ ano. O sexo masculino é o mais acometido e o quadro clínico predominante é de cefaléia e síndrome cerebelar. Nos adultos, essa neopla-sia localiza-se, preferencialmente, nos hemis-férios cerebelares, sendo o subtipo histológico desmoplásico mais freqüente. Na maioria dos casos, o tumor está limitado à fossa posterior ao diagnóstico. O tratamento inclui ressecção cirúrgica mais ampla possível, associada à radioterapia cranioespinhal com reforço em fossa posterior e, sempre que possível, quimioterapia adjuvante. O tratamento ade-quado permitirá um melhor controle da doença e uma maior sobrevida. A recidiva tardia é mais comum nos adultos, sendo necessário um longo seguimento desses pacientes. A sobrevida total de adultos com meduloblastomas parece ser maior que a das crianças com essa neoplasia. UNITERMOS Meduloblastoma, adulto, manifestações clíni-cas, tratamento. INTRODUÇÃO O meduloblastoma é uma neoplasia maligna primária do sistema nervoso central (SNC), de origem embrionária neuroepitelial, a partir de células pluripotenciais primitivas, que se desenvolve no cerebelo 1 . Quando esse tipo de tumor surge em qualquer outra parte do sistema nervoso central (SNC), como lesão primária, é chamado de tumor neuroectodérmico primitivo ou simplesmente "PNET" (Primitive Neuroectodermal Tumor). Os PNETs supra-tentoriais costumam ter comportamento mais heterogêneo que os medulo-blastomas, geralmente com pior resposta ao tratamento, por motivo ainda não bem esclarecido 2,3 . O meduloblastoma ocorre em todo o mundo e não existem evidências de que ele predomine em determinada subpopulação étnica ou racial 4 . Sua primeira definição como entidade clinicopatológica foi feita por Bailey e Cushing, em 1925 5 , como um tumor maligno do vérmis cerebelar, comum na infância, densamente celular, que ocupava o assoalho do IV ventrículo e determinava um prognóstico muito reservado, com curta sobrevida. Na infância, o meduloblastoma é a neoplasia maligna primária mais comum do sistema nervoso central (SNC), representando de 20% a 25% dos tumores encefálicos 6 e de 30% a 40% dos tumores de fossa posterior 7 . Na primeira década de vida, costuma haver uma distribuição bimodal, com picos em torno dos 3 e 5 anos e entre os 8 e 10 anos de idade 3,7 . Embora a maioria dos casos de meduloblastomas ocorram em crianças, 14% a 30% deles são encontrados em indivíduos maiores de 15 anos de idade 9,10,11 . Russell e Rubinstein (1989) 12 observaram que a incidência do meduloblastoma em adultos representa 1% do total dos tumores intracranianos e 6% dos tumores de fossa posterior. A incidência populacional do meduloblastoma em adultos (maiores de 16 anos) parece variar em torno de 0,5 por milhão/ano, a depender da população estudada, sendo nove a dez vezes menor que nas crianças 13,14,15. Em geral, a idade mediana dos pacientes adultos com meduloblastoma varia dentro do intervalo dos 20 aos 39 anos à época do diagnóstico, mais freqüentemente em torno dos 25 anos, mas pode surgir em qualquer idade, existindo descrições de casos desde os 16 até os 80 anos de idade ou mais 9,10,11,13 . De qualquer forma, cerca de 80% dos casos em adultos são diagnosticados antes dos 40 anos de idade 9,10,11,13 .
  • [Show abstract] [Hide abstract]
    ABSTRACT: The analysis of neuropsychological sequelae in children with brain tumors is a major concern in the debate for the definition of the therapeutic strategies. The authors review the recent literature in this field in the light of their own experience at the Gustave-Roussx Institute. Three main risk factors emerge from the analysis: radiation, age and surgical complications. The need for a longitudinal evaluation in these patients is emphasized in order to plan the subsequent appropriate readaptation.
    Archives de Pédiatrie 02/1998; 5(2):167-173. DOI:10.1016/S0929-693X(97)86832-7 · 0.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to compare three different techniques of delivering the posterior fossa boost in patients with medulloblastoma. Five patients underwent CT simulation for treatment planning of the posterior fossa boost. For each slice, the posterior fossa was contoured in addition to the cochlea, non-posterior fossa brain, pituitary gland, mandible, parotid glands, thyroid gland, pharynx, and cervical spinal cord. For each patient, plans for three techniques of delivering the posterior fossa boost were compared. Technique A utilized parallel-opposed lateral fields using bony landmarks (2-dimensional radiotherapy); the other two techniques were planned using 3-dimensional radiotherapy. Technique B utilized a pair of coplanar wedged posterior oblique beams, whereas Technique C utilized a pair of posterior oblique fields and a vertex field. Dose-volume histograms (DVH) were obtained for each of the organs contoured and for each technique and patient. The maximum, minimum, and mean dose to each organ were determined using the DVH program in our treatment planning system. In 3 of 5 patients, the planning target volume (PTV) was not included in the treatment field with Technique A. The cochlea received 100%, 50%, and 42% of the prescribed posterior fossa dose using Techniques A, B, and C respectively. The mean dose to the non-posterior fossa brain was highest with Technique C, intermediate with Technique A, and lowest for Technique B. The mean dose to the non-posterior fossa brain with Technique B was comparable to the mean non-posterior fossa brain dose delivered using parallel-opposed lateral fields based on the CT definition of the PTV. Likewise, mean dose to the pituitary gland was lowest for Technique B. Both Techniques B and C were associated with a higher mean dose to the thyroid gland, mandible, parotid glands, and pharynx. The use of Technique B minimized the radiotherapy dose to the cochlea, pituitary gland, and non-posterior fossa brain. Contrary to what one may expect, conformal radiotherapy using Technique B did not deliver a higher dose to the non-posterior fossa brain over standard parallel-opposed lateral fields. Other advantages of conformal techniques B and C over 2-dimensional radiotherapy are the inclusion of the PTV in all patients and a lower mean dose to the pituitary gland. The main disadvantage of conformal Techniques B and C employed in our patients is a higher mean dose to the thyroid gland and other tissues in the neck.
    International Journal of Radiation OncologyBiologyPhysics 02/2000; 46(2):281-6. DOI:10.1016/S0360-3016(99)00367-3 · 4.18 Impact Factor